Datamonitor Market Research Reports

Treatment Algorithms: Non-Small Cell Lung Cancer ? Molecular profiling will increasingly guide the choice of therapy

Tue, 09 Oct 2012 00:00:00 GMT

Despite advances in treatment, non-small cell lung cancer (NSCLC) remains a disease of poor prognosis, with an overall 5-year survival rate of just over 15%. The treatment of NSCLC is characterized by a high level of unmet need, most notably in the setting of advanced or metastatic disease, where outcomes are poor.Features and benefitsDisease overview assessing etiology, risk factors, symptoms and patient segmentationIn-depth analysis of most common treatment types according to stage at diagnosis and patient characteristicsAnalysis of physician prescribing trends in the six surveyed markets across all stages of diseaseAnalysis of possi...

Ironwood Pharmaceuticals: Company Analysis

Tue, 09 Oct 2012 00:00:00 GMT

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.Features and benefitsGain insight into Ironwood Pharmaceuticals' strategic outlookAnalyze company sales forecasts by productHighlightsLinaclotide is Ironwood Pharmaceuticals' most advanced product candidate. This drug is an orally administered gua...

Vertex Pharmaceuticals Inc.: Company Analysis

Tue, 09 Oct 2012 00:00:00 GMT

This analysis examines the historical and forecast performance for Vertex in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.Features and benefitsGain insight into Vertex's strategic outlook across the next 6 yearsAnalysis of strategically important company products, supported by patient-based forecasting and key opinion leader interviewsHighlightsStrategic evaluation of Vertex’s outlook for the next six years. Assessment of key strengths, weaknesses, opp...

NPS Pharmaceuticals, Inc.: Company Analysis

Tue, 09 Oct 2012 00:00:00 GMT

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.Features and benefitsGain insight into NPS Pharmaceuticals' strategic outlookAnalyze company sales forecasts by productHighlightsNPS Pharmaceuticals is a biotechnology company that is developing treatments for orphan endocrine and gastrointestinal dis...

Successes and Failures in Consumer Packaged Goods Innovation and Marketing in 2012

Fri, 05 Oct 2012 00:00:00 GMT

Effective innovation is difficult to come by, but it is the key to sustained competitive advantage in the consumer packaged goods (CPG) industry. This report compilation examines best-in-class examples of innovation and marketing - supported by Datamonitor's consumer insight research - to drive success in this increasingly challenging environment.Features and benefitsAccess 50 case studies of global successes and failures in the consumer packaged goods industry to drive ideation and inspiration.Obtain country-specific consumer insight to understand the consumer attitudes and needs that underpinned innovation success/failure.Avoid costly inv...

Epidemiology: COPD in China ? Aging, population growth, and increased survival will drive up prevalent cases over the next decade

Tue, 02 Oct 2012 00:00:00 GMT

Datamonitor's research shows that out to 2010, COPD will continue to be a major threat to Chinese adults. The number of prevalent cases of COPD will increase substantially between 2011 and 2021, increasing from approximately 42 million to nearly 56 million. This increase will be driven by demographic changes over the forecast period, including increased survival and a larger aged population.Features and benefitsGain insight to market potential, including a robust 10-year epidemiology forecast of COPD prevalent cases in China.Understand the key epidemiologic risk factors associated with COPD in China.HighlightsThe...

Consumer and Innovation Trends in Wine

Tue, 02 Oct 2012 00:00:00 GMT

While wine consumption is primarily driven by enjoyment and indulgence, new product development reflects the multifaceted motivations associated with buying and consuming wine. This brief outlines the most important consumer and product trends impacting the wine category globally, using Datamonitor’s TrendSights mega-trend framework as a basis to organize the key themes covered.Features and benefitsEach section is introduced with a concise SWOT analysis that outlines how each TrendSights mega-trend can be applied to the wine category.Consumer insight analysis covering 18 countries globally highlights the key attitudes and behaviors that drive cons...

Social Media in Financial Services: Building a Winning Strategy

Mon, 01 Oct 2012 00:00:00 GMT

Early pioneers have demonstrated the enormous benefits that can be gleaned from using social media to the rest of the financial services industry. Providers are becoming increasingly sophisticated in their utilization of social media. It is changing the way providers interact with their customers, impacting every area of the customer experience from marketing to customer service to brand building.Features and benefitsDiscover how to make the most of the opportunities offered by social media.Sculpt future strategies by harnessing lessons from best practice examples.Understand how your organization can be internally structured to use social media...

Best Practice Customer Acquisition Strategies in Banking

Mon, 01 Oct 2012 00:00:00 GMT

Customer acquisition can be expensive; therefore banks need to ensure that the strategies they use will be successful. Despite issues faced by the UK’s largest banks they still offer important examples of best practice acquisition strategies. Brand strategy, product innovation, and service delivery are three approaches utilized by these banks to build up an overall acquisition strategy.Features and benefitsImplement a successful acquisition strategy by learning from the largest providers in the UK.Acquire new customers through altering your brand strategy and innovating new products.Enrich your proposition with insight into global best pr...

Mobile Payments: Ringing the changes

Sat, 29 Sep 2012 00:00:00 GMT

The mobile payments market has expanded substantially in recent years, and after much speculation the sector is finally beginning to take shape. This report provides an overview of the different types of mobile payment now emerging, the challenges they face, and key player case studies on some of the most high profile service launched to date.Features and benefitsGain a better understanding of where your company fits into the mobile payments ecosystem through detailed market mapping and definitions.Plan effectively through up to date case studies of mobile payment developments globallyUnderstand where the market may be heading with Datamonitor&...

Product Profiles: Top 20 Oncology Therapy Brands 2011-21

Thu, 27 Sep 2012 00:00:00 GMT

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. The treatment of cancer has shifted away from mass market blockbuster cytotoxic drugs toward a more personalized therapy approach. However, government austerity packages could see slower commercial growth and larger generic erosion of key brands.Features and benefitsAssess detailed drug information for the leading oncology brands, including detailed clinical trial information for each approved indicationUnderstand the key factors that led to the success of the top 20 oncology therapy brands and the obstacles that...

AstraZeneca plc: Company Analysis

Thu, 27 Sep 2012 00:00:00 GMT

This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.Features and benefitsGain insight into AstraZeneca's strategic outlook across the next 6 yearsAnalyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and sourceHighlightsStrategic insight into the prospects for AstraZeneca over the next six years. Picking out key strengths, wea...

UK Private Motor Insurance 2012

Thu, 27 Sep 2012 00:00:00 GMT

After continued hardening in 2011, softening rates have returned in 2012. Insurers achieving profitability last year will benefit here while others face a stark choice between driving for profit and defending market share. In this environment it will be key to achieve full potential from distribution, find opportunities in customer behavior and understand position in relation to the competition.Features and benefitsBenchmark your performance against the whole market by book growth, profitability, and claims experience.Discover how both insurers and consumers are responding to new and emerging products.Inform your brand strategy with insight int...

Brazil Pharmaceutical Market Overview ? Strong market growth continues, but regulatory risks increase

Fri, 21 Sep 2012 00:00:00 GMT

Key growth drivers in Brazil include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to offset slowing sales growth in more developed markets.Features and benefitsAnalysis of population demographics, economic wealth, disease burden, level of industrialization, and political structure in Brazil.Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, and intellectual property position in Brazil.Assesses the generics and biosimilars landscape in terms of regulatory issues, level of pen...

Market and Product Forecasts: Top 10 Neurology Brands: 2011?21

Thu, 20 Sep 2012 00:00:00 GMT

The diverse field of neurology hosts numerous disorders with substantial unmet clinical need, creating a complex but lucrative market. Considerable rewards are available for the manufacturers of successful neurological therapies, as effective lifecycle management and the pitfalls of R&D can insulate brands from competition. The neurology market is set to remain an attractive long-term prospect.Features and benefitsAccess sales-based forecast of leading neurology brands in the seven major markets over 2011–2021, with transparent methodology and clear assumptions.Gauge the relative successes of the top 10 neurology brands over a 10-year time per...

UK Plastic Cards: Market Sizing and Forecasting

Thu, 20 Sep 2012 00:00:00 GMT

Despite the UK economy re-entering recession, the payment card market has continued to perform relatively well. This has been primarily driven by consumer preference for debit card payments. With the huge write-offs of 2009 and 2010 behind it, the credit card market in H1 2012 is also registering its first overall growth figures since before the economic crisis began.Features and benefitsIncludes detailed analysis of macro-economic indicators and how these factors will affect the card market in 2013.Providing the latest data, the report focuses on key metrics such as card transaction values, balances, and card numbers.By using the latest availa...

Consumer and Innovation Trends in Meat, Fish, and Poultry

Thu, 20 Sep 2012 00:00:00 GMT

As consumer trends drive innovation and purchasing behavior it is increasingly vital to understand how to shape products to best meet these. This brief outlines the most important consumer and product trends impacting the meat, fish, and poultry category globally, using Datamonitor’s TrendSights mega-trend framework as a basis to organize the key themes covered.Features and benefitsEach section contains a concise SWOT analysis that outlines how each TrendSights mega-trend can be applied to the meat, fish, and poultry category.Consumer insight analysis covering 20 countries highlights the key attitudes and behaviors driving consumers’ meat, f...

Consumer and Innovation Trends in Sauces, Dressings, and Condiments

Thu, 20 Sep 2012 00:00:00 GMT

Growth in home cooking has driven consumers to explore new flavors inspired by global cuisines. Sauces, dressings, and condiments offer a combination of convenience and versatility to enhance consumers' eating experiences. This report outlines relevant consumer and product trends impacting this category globally, based on Datamonitor’s TrendSights mega-trend framework to classify the key themes.Features and benefitsEach section contains a concise SWOT analysis that outlines how each TrendSights mega-trend can be applied to the SDC category.Consumer insight analysis covering 20 countries globally highlights the key attitudes and behaviors drivi...

Market and Product Forecasts: Asthma ? Premium products to offset loss to generics

Fri, 07 Sep 2012 00:00:00 GMT

The asthma market has seen strong growth, with increased uptake of relatively expensive combination products. This trend is expected to change in the near future as sales growth will slow, and even turn negative, as key products face generic entry. However, by 2021, Datamonitor forecasts a return to positive growth such that the market will maintain value, with a CAGR over 2012–21 of 0.1%.Features and benefitsAccess Datamonitor’s patient-based asthma market forecast for the seven major markets, with transparent methodology and clear assumptions.Understand how market dynamics are changing and which drug classes will be most impacted in the ne...

Central Nervous System Drug Delivery Specialists

Wed, 05 Sep 2012 00:00:00 GMT

The blood-brain barrier (BBB) is so effective at limiting the passage of exogenous substances that many drugs with the potential to treat CNS diseases are rendered ineffective by their inability to reach their target. Consequently, companies that develop innovative delivery technologies are in a position to play a vital role in CNS drug development.Features and BenefitsIdentify the leading companies with innovative technologies designed to enhance CNS drug delivery.Compare the technologies that each company has developed and the diseases to which they are being applied.Evaluate each company’s pipeline of products and the intellectual...

Delivery Across the Blood-Brain Barrier

Wed, 05 Sep 2012 00:00:00 GMT

The blood-brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB) exist to protect the brain, stringently regulating the passage of substances in and out. This report examines the ways in which these natural barriers may be overcome or circumvented to ensure that drugs can reach their intended target in the brain.Features and BenefitsUnderstand the functions of the blood-brain barrier and the reasons why it presents a significant challenge in development of CNS drugs.Identify the five main strategies for maximizing the delivery of drugs to the brain.Understand the scientific basis of the most promising and recent technology a...

Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011

Mon, 03 Sep 2012 00:00:00 GMT

The high level of commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers. Treatment of cancer has shifted toward a more focused attack on the disease with targeted therapies. However, austerity packages imposed could see slower commercial growth and larger generic erosion of key brands.Features and BenefitsAnalysis of the top 20 oncology therapy brands in the seven major marketsIn depth analysis of the factors influencing the top 20 oncology brands in individual countries of the seven major marketsSales forecasts for the top 20 cancer therapy brands from 201...

Drug Discovery in Rare Diseases

Fri, 31 Aug 2012 00:00:00 GMT

In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This report examines the role that low disease prevalence plays in determining the most suitable R&D path.Features and benefitsUnderstand the growing interest in developing new treatments for rare diseases, and why low patient numbers do not preclude commercial viability.Review the regulatory environment governing the development of orphan drugs in different countries.Identify the key challenges that are presented by low patient prevalences.<...

Emerging Pharma Company Analysis: Onyx Pharmaceuticals

Thu, 30 Aug 2012 00:00:00 GMT

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.Features and benefitsPatient-based forecasts for Onyx's lead pipeline candidate, Kyprolis (carfilzomib), supported by key opinion leader researchAssessment of Onyx's corporate strategy, operating performance, and earlier-stage pipelineHighlightsIn...

UK Private Medical Insurance 2012

Thu, 30 Aug 2012 00:00:00 GMT

This report gives a comprehensive analysis of the UK private medical insurance sector. Three exclusive surveys provide insight into consumer trends and intermediaries attitudes towards private medical insurance. For the first time this report also highlights where advisors expect to see growth in 2013.Features and benefitsKey consumer insight in to individual trends, attitudes and buying behaviour.Market analysis and extensive data on the key players within the PMI market.The future of the PMI market according to intermediaries, including where their focus will be in 2013.Access Datamonitor's forecasts on the PMI market, looking at...